A Study of OPC-262 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in
patients with type 2 diabetes by repeated administration orally for 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.